Tardive Dyskinesia

Latest News

valbenazine
New Ingrezza Data Demonstrates Functional and Quality of Life Improvements in Patients With Tardive Dyskinesia

May 16th 2025

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

tardive dyskinesia
New 48-Week Remission Data on Ingrezza for the Treatment of Tardive Dyskinesia

March 20th 2025

phase 1
Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions

March 5th 2025

tardive dyskinesia
Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia

February 27th 2025

innovation
Psychopharmacology Innovations

December 10th 2024

Video Series
Video Interviews
Podcasts
tardive versus spontaneous dyskinesia

More News

© 2025 MJH Life Sciences

All rights reserved.